Chronic Kidney Disease (CKD) Platelet Study

Inclusion Criteria: 1. Males and females, aged 18-91 years 2. Ability to understand and sign informed consent after the nature of the study has been fully explained 3. CKD participants: Non-dialysis CKD patients: Presence of CKD with an estimated GFR of \<30 mL/min/1.73 m2 for a period of ≥3 months, as defined by the National Kidney Foundation (NKF) and determined with the CKD-EPI creatinine-based formula 4. Controls with normal kidney function: participants with an estimated GFR \>90 mL/min/1.73 m2 as determined by the CKD-EPI creatinine-based formula and a urine albumin-to-creatinine ratio \<30 mg/g as defined by the National Kidney Foundation Exclusion Criteria: * No healthcare power of attorney to sign informed consent * Unwillingness or inability to participate in the protocol or comply with any of its components. * Subjects unable or unwilling to stop taking: * Aspirin and other antithrombotic agents, like cilostazol, ranolazine, aggrenox, prasugrel, warfarin, xarelto, pradaxa, eliquis. * Glycoprotein IIb/IIIa antagonist (abciximab-ReoPro, eptifibatide-Integrilin, tirofiban-Aggrastal) * NSAIDs and PPIs * Fish oil, Vitamin E and herbal supplements * Acute kidney injury superimposed on CKD * Kidney transplant or any other solid organ transplant recipient * End-stage kidney disease on maintenance dialysis (peritoneal or hemodialysis) * Nephrotic syndrome defined as nephrotic range proteinuria, hypoalbuminemia, hyperlipidemia and generalized edema * Recent hospitalization or surgery \<3 months * Acute coronary or cerebrovascular event in the last 12 months * Blood dyscrasias, active bleeding, or bleeding diathesis * Gastrointestinal bleeding in the last 6 months * Recent treatment (\<30 days) with a glycoprotein IIb/IIIa antagonist (Integrelin). * Hematocrit \<25%, white blood cell count \>20,000/μL, or platelet count \<50,000/μL * Any active malignancy or liver disease. * Pregnancy * Positive urine pregnancy test in a woman of childbearing potential prior to study entry. A female of childbearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * Has not undergone a hysterectomy or bilateral oophorectomy; or * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). * Patients must not be nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.